Xilio Therapeutics dosed the first patient in a Phase 1/2 study for its PD-1 and masked IL-2 bispecific, with data expected in late 2027, highlighting further progress in its immuno-oncology pipeline.
Xilio Therapeutics dosed the first patient in a Phase 1/2 study for its PD-1 and masked IL-2 bispecific, with data expected in late 2027, highlighting further progress in its immuno-oncology pipeline.